Core Insights - Jinghua Pharmaceutical's stock increased by 0.25% on November 11, with a trading volume of 182 million yuan, indicating active market participation [1] - The company reported a financing buy of 12.04 million yuan and a financing repayment of 16.41 million yuan on the same day, resulting in a net financing outflow of 4.37 million yuan [1] - As of November 11, the total margin balance for Jinghua Pharmaceutical was 177 million yuan, representing 2.71% of its market capitalization [1] Financing and Margin Data - On November 11, the financing buy amounted to 12.04 million yuan, while the current financing balance stands at 177 million yuan, which is above the 70th percentile of the past year [1] - The short selling data shows no shares were sold or repaid on November 11, with a remaining short position of 2,000 shares and a short balance of 16,000 yuan, indicating a low level of short selling activity [1] Company Overview - Jinghua Pharmaceutical, established on January 3, 1994, and listed on February 3, 2010, is based in Nantong, Jiangsu Province [1] - The company's main business includes the research, production, and sales of traditional Chinese medicine preparations, chemical raw materials, and biopharmaceuticals [1] - The revenue composition is as follows: traditional Chinese medicine preparations (39.22%), chemical pharmaceutical intermediates (23.51%), chemical raw materials (20.79%), and Chinese medicinal materials (15.80%) [1] Financial Performance - For the period from January to September 2025, Jinghua Pharmaceutical achieved a revenue of 1.092 billion yuan, reflecting a year-on-year growth of 4.51% [2] - The net profit attributable to shareholders for the same period was 176 million yuan, showing a year-on-year increase of 7.39% [2] Shareholder and Dividend Information - Since its A-share listing, Jinghua Pharmaceutical has distributed a total of 533 million yuan in dividends, with 205 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.36% to 88,800, while the average number of circulating shares per person increased by 7.94% to 9,167 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.8555 million shares, a decrease of 1.6727 million shares from the previous period [3]

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [1][5] Core Views - The company has shown a recovery in performance with revenue and profit growth. For the first three quarters of 2025, the company achieved revenue of 411 million yuan, a year-on-year increase of 5.90%, and a net profit attributable to the parent company of 104 million yuan, up 13.45% year-on-year [3][5] - The company focuses on a multi-dimensional product layout and market expansion, primarily leading with APIs while extending into new materials and ensuring a solid reserve of intermediates [5][6] - The company plans to register 1-2 new API varieties annually and is actively pursuing registrations for both old and new products in high-end regulatory markets in Europe and the United States [5][6] Financial Performance Summary - For the first three quarters of 2025, the company reported a gross margin of 47.15%, an increase of 3.61 percentage points year-on-year, and a net margin of 26.31%, up 2.20 percentage points year-on-year [5] - The company’s Q3 revenue was 150 million yuan, representing a 29.45% increase, with a net profit of 35.73 million yuan, up 64.79% year-on-year [5] - The company’s financial forecasts for 2025-2027 indicate expected revenues of 604.89 million yuan, 662.66 million yuan, and 765.83 million yuan, with corresponding net profits of 147.17 million yuan, 170.59 million yuan, and 201.32 million yuan [6][8] Market Position and Strategy - The company is enhancing its competitiveness by extending its industrial chain and exploring emerging markets, aiming for a transition towards proprietary APIs [5][6] - The company has successfully formed commercial orders for new products, indicating a robust pipeline and commitment to innovation [5][6] - The company’s first major shareholder is Jinghua Pharmaceutical Group Co., Ltd., holding a 72.31% stake, which provides a strong backing for its strategic initiatives [1][5]

Core Insights - On October 16, Jinghua Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 70.49 million yuan [1] - The company experienced a net financing outflow of 5.15 million yuan on the same day, with a total financing balance of 163 million yuan, representing 2.74% of its market capitalization [1] - As of June 30, 2025, Jinghua Pharmaceutical reported a revenue of 731 million yuan, a year-on-year increase of 1.54%, while its net profit attributable to shareholders decreased by 3.54% to 131 million yuan [2] Financing and Margin Trading - On October 16, the financing buy amount for Jinghua Pharmaceutical was 3.10 million yuan, with a total financing balance of 163 million yuan, which is below the 40th percentile of the past year [1] - The company had a margin trading balance of 67,400 yuan, with a short selling volume of 0 shares on October 16, indicating low activity in this area [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Jinghua Pharmaceutical was 95,900, a decrease of 5.29% from the previous period, while the average number of circulating shares per person increased by 5.58% to 8,492 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.48 million shares to 8.53 million shares, while the Huatai-PineBridge CSI Traditional Chinese Medicine ETF reduced its holdings by 243,700 shares to 2.68 million shares [3]

Core Insights - The stock of Jinghua Pharmaceutical experienced a decline of 0.40% on September 17, with a trading volume of 64.30 million yuan [1] - As of September 17, the company had a total margin balance of 180 million yuan, with a financing net buy of -1.63 million yuan for the day [1][2] - The company reported a revenue of 731 million yuan for the first half of 2025, reflecting a year-on-year growth of 1.54%, while the net profit attributable to shareholders decreased by 3.54% to 131 million yuan [2][3] Financing and Margin Data - On September 17, Jinghua Pharmaceutical had a financing buy of 7.10 million yuan and a financing repayment of 7.26 million yuan, resulting in a net financing buy of -0.16 million yuan [1] - The current financing balance of 180 million yuan accounts for 2.94% of the circulating market value, which is above the 70th percentile of the past year [1] - The company had a margin balance of 28,500 yuan with a remaining short position of 3,800 shares, indicating a low level of short selling activity [1] Shareholder and Dividend Information - As of June 30, the number of shareholders for Jinghua Pharmaceutical was 95,900, a decrease of 5.29% from the previous period [2] - The company has distributed a total of 533 million yuan in dividends since its A-share listing, with 205 million yuan distributed in the last three years [3] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.48 million shares, and a new entry from the Traditional Chinese Medicine ETF [3]

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of 0.785060 RMB per 10 shares, following an increase in total shares due to the issuance of restricted stock [2][5]. Summary by Sections Share Capital and Dividend Distribution - The company completed the registration of 15,494,000 new shares, increasing the total share capital from 814,180,908 shares to 829,674,908 shares [2][3]. - The cash dividend for 2024 is set at 0.785060 RMB per 10 shares, with a total cash distribution amounting to approximately 65.13 million RMB [2][5]. Adjustments to Dividend Distribution - The cash dividend distribution will be adjusted based on the new total share capital, ensuring that the total cash dividend remains unchanged [3][5]. - The adjusted cash dividend per share is calculated to be approximately 0.078506 RMB after the increase in total shares [3]. Key Dates - The record date for the dividend distribution is set for June 5, 2025, and the ex-dividend date is June 6, 2025 [6]. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their securities companies on the ex-dividend date [8]. Consultation and Documentation - The company has provided contact information for inquiries and has listed documents available for review regarding the dividend distribution [10].

证券代码：002349 证券简称：精华制药 公告编号：2025-002 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"）原指定的信息披露媒体为《证 券时报》及巨潮资讯网（http://www.cninfo.com.cn）。因与《证券时报》签订的 信息披露服务协议于 2025 年 2 月 28 日到期，2025 年 3 月 1 日起公司指定信息披露 媒体变更为《中国证券报》及巨潮资讯网（http://www.cninfo.com.cn）。 关于变更指定信息披露媒体的公告 精华制药集团股份有限公司董事会 2025 年 3 月 1 日 公司所有公开披露的信息均以在《中国证券报》及巨潮资讯网 （http://www.cninfo.com.cn）上刊登的正式公告为准，敬请广大投资者知悉。 公司对《证券时报》以往提供的优质服务表示衷心的感谢！ 精华制药集团股份有限公司 特此公告。 ...